SCHEMBL20183507

SCHEMBL20183507

CCn1c(=O)cc(C2CCN(C)CC2)c2cc(C(=O)N3CCCc4ccccc43)ccc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.48
PDE4B Q07343 1/20 0.48
PDE4C Q08493 1/20 0.48
PDE4D Q08499 1/20 0.48
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
TSHR P16473 5/20 0.46
ALDH1A1 P00352 4/20 0.46
HPGD P15428 2/20 0.46
POLB P06746 1/20 0.46
MAPT P10636 1/20 0.46
AVPR2 P30518 2/20 0.46
OXTR P30559 2/20 0.46
AVPR1A P37288 2/20 0.46
USP2 O75604 1/20 0.46
LMNA P02545 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
CRBN Q96SW2 1/20 0.46
KDM4E B2RXH2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20183531 0.95 SMN1; SMN2 (0.52) KMT2AMEN1TSHRALDH1A1HPGD
SCHEMBL21549541 0.86 SMN1; SMN2 (0.41) KMT2AMEN1TSHRALDH1A1HPGD
SCHEMBL20183532 0.84 MEN1 (0.53) PDE4APDE4BPDE4CPDE4DKMT2A
SCHEMBL23234300 0.82 GAA (0.47) KMT2AMEN1TSHRALDH1A1HPGD
SCHEMBL20354277 0.82 ALDH1A1 (0.48) KMT2AMEN1ALDH1A1POLBLMNA
SCHEMBL20183697 0.81 KDM4E (0.48) KMT2AMEN1TSHRALDH1A1HPGD
SCHEMBL20183657 0.81 PDE4A (0.45) PDE4APDE4BPDE4CPDE4DKMT2A
SCHEMBL15126341 0.81 MEN1 (0.57) PDE4APDE4BPDE4CPDE4DKMT2A
SCHEMBL20195127 0.78 KDM4E (0.36) KMT2AMEN1TSHRALDH1A1HPGD
SCHEMBL21549568 0.77 KDM4E (0.39) KMT2AMEN1TSHRALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10987349-B2 Antitumor agent and bromodomain inhibitor FUJIFILM CORPORATION (JP) 2021-04-27 US claimed
EP-3563851-B1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM CORP (JP) 2021-04-21 EP claimed
EP-3563851-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM Corporation (JP) 2019-11-06 EP claimed
US-20190314360-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM CORPORATION (JP) 2019-10-17 US claimed
CN-108137505-B Nitrogen-containing heterocyclic compound 富士胶片株式会社 2021-07-06 CN disclosed
US-10987349-B2 Antitumor agent and bromodomain inhibitor FUJIFILM CORPORATION (JP) 2021-04-27 US disclosed
EP-3563851-B1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM CORP (JP) 2021-04-21 EP disclosed
EP-3563851-B1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM CORP (JP) 2021-04-21 EP disclosed
EP-3327004-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND FUJIFILM CORP (JP) 2020-11-04 EP disclosed
US-10696637-B2 Nitrogen-containing heterocyclic compound FUJIFILM CORPORATION (JP) 2020-06-30 US disclosed
US-10696637-B2 Nitrogen-containing heterocyclic compound FUJIFILM CORPORATION (JP) 2020-06-30 US disclosed
US-10633343-B2 2020-04-28 US disclosed
US-10633343-B2 2020-04-28 US disclosed
EP-3563851-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM Corporation (JP) 2019-11-06 EP disclosed
US-20190314360-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM CORPORATION (JP) 2019-10-17 US disclosed
US-20190077761-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND FUJIFILM CORPORATION (JP) 2019-03-14 US disclosed
US-20190077761-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND FUJIFILM CORPORATION (JP) 2019-03-14 US disclosed
WO-2018124180-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR 富士フイルム株式会社 2018-07-05 WO disclosed
EP-3327004-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Fujifilm Corporation (JP) 2018-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10987349-B2 Antitumor agent and bromodomain inhibitor BRD4, BRD1, BRD3 PDE4A 3862/4885PDE4B 3978/4885PDE4C 4245/4885
US-10696637-B2 Nitrogen-containing heterocyclic compound CXCL10, CCL5, CXCR3 PDE4A 2164/4885PDE4B 2335/4885PDE4C 2061/4885
US-20190314360-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR BRD4, BRD1, BRD3 PDE4A 3862/4885PDE4B 3978/4885PDE4C 4245/4885
US-20190077761-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND CXCL10, CCL5, CXCR3 PDE4A 2164/4885PDE4B 2335/4885PDE4C 2061/4885
US-10633343-B2 CXCL10, CCL5, CXCR3 PDE4A 1851/4885PDE4B 2140/4885PDE4C 1869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.